Professor Richard Anderson Scientific & Clinical Advisor Richard Anderson is Elsie Inglis Professor of Clinical Reproductive Science, and Head of Section, Obstetrics and Gynaecology at the [...]
Dr H Joffe Scientific & Clinical Advisor Dr H Joffe, MD, MSc, is the Paula A. Johnson Associate Professor of Women’s Health at Harvard Medical School, where she serves as the Executive [...]
Elizabeth Ballantyne Head of Clinical Operations Liz has over 25 years’ experience in Clinical Operations and Clinical Development across the pharmaceutical and CRO industries, with experience [...]
Dr Steve Pawsey Chief Medical Officer An anaesthetist by training, Steve has extensive experience in the global pharmaceutical and biotechnology sectors, having worked in a broad range of [...]
Dr Mike Trower Co-Founder, Chief Scientific Officer & Chief Operating Officer Mike Trower has more than 25 years’ drug discovery and development experience in the pharmaceutical and [...]
First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value [...]
Launched in 2017, KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions.
Please fill out the form to get in touch with us.